Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...

Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells. Experts say it offers improved outcomes in several advanced cancers and ...

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...

In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent ...

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 ...

Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for American patients.